Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers

The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affe...

Full description

Bibliographic Details
Main Authors: Iñigo Landa, Jeffrey A. Knauf
Format: Article
Language:English
Published: Korean Endocrine Society 2019-02-01
Series:Endocrinology and Metabolism
Subjects:
Online Access:https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-34-11.pdf
_version_ 1828910821755846656
author Iñigo Landa
Jeffrey A. Knauf
author_facet Iñigo Landa
Jeffrey A. Knauf
author_sort Iñigo Landa
collection DOAJ
description The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 (TP53) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase (TERT) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAFV600E-driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAFV600E-driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAFV600E-driven thyroid cancers.
first_indexed 2024-12-13T18:51:25Z
format Article
id doaj.art-c5318217c3054495a5b27d3a9c56c0da
institution Directory Open Access Journal
issn 2093-596X
2093-5978
language English
last_indexed 2024-12-13T18:51:25Z
publishDate 2019-02-01
publisher Korean Endocrine Society
record_format Article
series Endocrinology and Metabolism
spelling doaj.art-c5318217c3054495a5b27d3a9c56c0da2022-12-21T23:34:56ZengKorean Endocrine SocietyEndocrinology and Metabolism2093-596X2093-59782019-02-01341112210.3803/EnM.2019.34.1.11Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid CancersIñigo Landa0Jeffrey A. Knauf1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, .USAHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, .USAThe development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 (TP53) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase (TERT) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAFV600E-driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAFV600E-driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAFV600E-driven thyroid cancers.https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-34-11.pdfProto-oncogene proteins B-rafThyroid neoplasmsMice, transgenic
spellingShingle Iñigo Landa
Jeffrey A. Knauf
Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
Endocrinology and Metabolism
Proto-oncogene proteins B-raf
Thyroid neoplasms
Mice, transgenic
title Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
title_full Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
title_fullStr Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
title_full_unstemmed Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
title_short Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers
title_sort mouse models as a tool for understanding progression in braf driven thyroid cancers
topic Proto-oncogene proteins B-raf
Thyroid neoplasms
Mice, transgenic
url https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-34-11.pdf
work_keys_str_mv AT inigolanda mousemodelsasatoolforunderstandingprogressioninbrafdriventhyroidcancers
AT jeffreyaknauf mousemodelsasatoolforunderstandingprogressioninbrafdriventhyroidcancers